若生智能
Drug Database
TR

treprostinil

✓ Approved

United Therapeutics · PTGIR · 小分子

什么是 treprostinil？

treprostinil 是一种小分子，由United Therapeutics研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

公司United Therapeutics
药物类别小分子
分子靶点PTGIR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, United Therapeutics

作用机制

分子靶点

treprostinil 作用于 1 个分子靶点：

PTGIRprostaglandin I2 receptor (IP, PRIPR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

treprostinil 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersPulmonary hypertension✓ Approved

相关研究文献

PubMedJACC. Case reports2026-07-30

Pseudo-Infarction Reversal in Right Precordial Leads: ECG Evolution in Severe Pulmonary Hypertension.

Wang Lina L, Cui Yuxia Y, Song Jing J, Zhao Qinghao Q et al.

An acute pulmonary hypertension (PH) crisis causes dynamic electrocardiographic (ECG) changes, but complete post-therapy normalization-especially in post-transplant thrombotic microangiopathy (TMA) patients-is rarely documented. A 53-year-old man with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation presented with dyspnea. Right heart catheterization confirmed an acute pulmonary hypertension crisis (mean pulmonary arterial pressure: 52 mm Hg) secondary to thrombotic microangiopathy. Treatment with inhaled nitric oxide and treprostinil led to improvement. Follow-up echocardiography showed normalized pulmonary arterial pressure (35 mm Hg), resolution of ECG abnormalities (including a myocardial infarction pattern in the right precordial leads), and no PH recurrence. This case highlights TMA as a rare cause of reversible, vasoreactive PH after hematopoietic stem cell transplantation and documents the full ECG evolution during PH crisis and recovery. ECG monitoring is essential for diagnosing and tracking acute PH crises in transplant patients. Post-transplant TMA can cause reversible PH, requiring prompt hemodynamic assessment and targeted therapy.

PMID 42530193
阅读全文 →
PubMedFrontiers in pharmacology2026-07-23

Pharmacovigilance assessment of gout: a real-world study using the FAERS database.

Ren Honghao H, Yao Nannan N, Ren Xiaodong X, Su Yani Y et al.

Drug intervention is a key method for preventing gout, various drugs have been implicated as potential risk factors in individual studies. This study aims to comprehensively identify drugs linked to the development of gout. Data were obtained from the FDA Adverse Event Reporting System (FAERS), and disproportionality analysis was employed to quantitatively assess the associations between drugs and gout. Four complementary signal detection methods-Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)-were utilized. To further delineate exposure-outcome relationships and identify influential predictors, least absolute shrinkage and selection operator (LASSO) logistic regression was implemented. Time-to-onset (TTO) analysis was conducted to examine the temporal dynamics between drug initiation and the occurrence of gout. Finally, a comprehensive assessment of the therapeutic indications of the drugs was performed. A total of 35 drugs were ultimately identified as potentially associated with the onset and progression of gout. Among these, several agents have been previously reported in the literature as having possible links to gout development. In addition, a number of novel candidates were detected for which evidence of an association with gout remains limited or has not been clearly established. These include Lenalidomide, Sacubitril valsartan, Ruxolitinib, Treprostinil, Octreotide, Selexipag, Rosuvastatin, Sitagliptin, Riociguat, Epoprostenol, Patiromer, Dasabuvir ombitasvir paritaprevir ritonavir, Tafamidis, Sparsentan, and Iloprost. Furthermore, TTO analysis suggested that approximately 75% of gout events occurred within 0.6 years following initiation of therapy. These pharmacotherapeutic agents are employed across diverse clinical settings, encompassing haematological malignancies, cardiovascular diseases, and pulmonary hypertension. These findings suggest the potential for targeted monitoring of drug-associated gout in clinical practice. When administering these medications, it may be crucial to regularly assess patients' uric acid levels and maintain heightened awareness for the possible onset of gout.

PMID 42488563
阅读全文 →
PubMedMed (New York, N.Y.)2026-07-11

Inhaled treprostinil and the vascular turn in pulmonary fibrosis.

Yanagihara Toyoshi T, Kolb Martin M

TETON trials recently evaluated inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) using two parallel phase 3 studies in different world regions. Both met the primary endpoint, demonstrating significantly less one-year forced vital capacity decline versus placebo. This viewpoint critically appraises the findings and contextualizes them within the evolving IPF treatment landscape.

PMID 42431188
阅读全文 →
PubMedTranslational pediatrics2026-07-11

Perioperative management of emergency non-cardiac surgery in a pediatric patient with Eisenmenger syndrome: a case report.

Jiang Chenjia C, Zhao Jialian J, Zhao Jiajia J, Huang Wenfang W et al.

Eisenmenger syndrome (ES) is a late-stage complication of untreated congenital heart disease. It is characterized by irreversible pulmonary arterial hypertension (PAH), right-to-left shunting, and cyanosis. Pediatrics with ES who undergo emergency non-cardiac surgery are at an extremely high perioperative risk. Potential complications include pulmonary hypertension crisis (PHC), right ventricular failure, and sudden cardiac death. There is limited evidence guiding perioperative management in this population. An 11-year-old girl required emergency surgery under general anesthesia for right ovarian torsion. She had a history of congenital heart disease, which was complicated by severe pulmonary hypertension (pulmonary artery pressure: 105/49 mmHg) and ES. Anesthesia was inducted with etomidate, midazolam, vecuronium, and sufentanil, and maintained with propofol, remifentanil and sevoflurane. Intraoperatively, hemodynamic parameters remained stable. However, the patient developed a postoperative PHC, which was characterized by ventricular tachycardia, hypotension, and hypoxemia. Prompt treatment with amiodarone, treprostinil, sodium bicarbonate, and supplemental oxygen successfully restored sinus rhythm and hemodynamic stability. The patient was discharged on postoperative day 11. Emergency non-cardiac surgery poses an extremely high anesthetic risk for pediatrics with ES. It is critical to avoid factors that elevate pulmonary vascular resistance, ensure meticulous monitoring, and recognize and treat PHC early. This case underscores the importance of personalized anesthetic planning and multidisciplinary perioperative management for this vulnerable population.

PMID 42433959
阅读全文 →
PubMedProstaglandins, leukotrienes, and essential fatty acids2026-07-02

Cardiovascular safety profile of prostaglandin E and prostacyclin analogues: Clinical reports and ex vivo studies on human coronary arteries.

Merheb Gaelle G, Abdelazeem Heba H, Senbel Amira A, Moude Izza I et al.

Prostaglandin E1 (PGE1), prostaglandin E2 (PGE2), prostacyclin and their analogues are widely used in clinical practice for their potent biological effects. PGE1/PGE2 analogues, including misoprostol and sulprostone, are primarily used in obstetrics for labour induction, abortion, and postpartum haemorrhage management, whereas PGI2 analogues such as iloprost and treprostinil are key drugs in pulmonary arterial hypertension treatment. Despite structural similarities, these compounds produce contrasting vascular effects due to differences in receptor selectivity, signalling pathways, and tissue distribution. PGE1/PGE2 analogues activate EP receptors, particularly EP1 and EP3 with varying selectivity profile, promoting vasoconstriction and have been associated with cardiovascular complications such as coronary vasospasm. In contrast, PGI2 analogues act mainly on IP receptors, promoting vasodilation, inhibition of platelet aggregation, and beneficial vascular remodelling, with a generally favourable cardiovascular safety profile. Although cardiovascular effects have been reported with both classes of analogues, the underlying mechanisms, and especially their direct effects on human coronary arteries (HCA) remain insufficiently explored. In this context, we combined a review of the clinical and experimental literature that integrates clinical reports with original ex vivo pharmacological investigations on isolated HCA. Both PGE2 and misoprostol induce concentration-dependent vasoconstriction, primarily via EP3 receptors, which is significantly reduced by a TP receptor antagonist, suggesting a potential EP3-TP pathway interaction. All tested PGI2 analogues consistently induced relaxation in our HCA preparations, a finding that aligns with their general improvement of cardiovascular clinical parameters, with only rare exceptions. Together, these findings summarize the cardiovascular effects of clinically-used prostanoids and provide mechanistic insights to optimize their therapeutic use while minimizing cardiovascular risk.

PMID 42385560
阅读全文 →
PubMedExpert review of respiratory medicine2026-06-23

A profile on inhaled treprostinil for pulmonary hypertension.

El-Kersh Karim K, Shamsid-Deen Nafis N

Pulmonary hypertension (PH) remains a progressive and life-threatening disease despite advances in therapies targeting multiple signaling pathways. Prostacyclin analogues play a central role in treatment; however, systemic formulations can be limited by treatment burden and systemic adverse effects. Inhaled treprostinil has emerged as an important prostacyclin-pathway therapy that allows targeted pulmonary artery vasodilation while minimizing systemic exposure, with relevance for pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). This review provides a comprehensive overview of the pharmacology, pharmacokinetics, and clinical development of inhaled treprostinil across both currently available and investigational formulations. All major clinical trials are examined, including pivotal early Phase I-II investigations. We discuss all commercially available and emerging delivery platforms including nebulized, dry-powder, liposomal, and prodrug formulations. In addition, the review addresses safety, real-world utilization, regulatory status, and the evolving therapeutic and commercial landscape of inhaled prostacyclin therapy. Inhaled treprostinil has become a key treatment option in PH-ILD and PAH management. Continued development of longer-acting formulations and improved delivery systems may enhance adherence and expand its clinical role. Emerging evidence suggesting potential antifibrotic effects raises the possibility that inhaled treprostinil could influence disease progression in pulmonary fibrosis, potentially broadening its therapeutic applications in the coming years.

PMID 42334442
阅读全文 →

注册免费账户还可查看另外 893 篇文献

免费注册查看全部文献 →

了解更多treprostinil